Modality
Degrader
MOA
CAR-T CD19
Target
IL-17A
Pathway
Complement
PsoriasisHemophilia AT2D
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
~Dec 2020
→ ~Mar 2022
Phase 2
Jun 2022
→ Apr 2031
Phase 2Current
NCT04089551
2,836 pts·Psoriasis
2025-05→2028-07·Active
NCT05807395
242 pts·T2D
2022-06→2031-04·Recruiting
3,078 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-07-212.3y awayPh2 Data· Psoriasis
2031-04-185.0y awayPh2 Data· T2D
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Recruit…
P2
Active
Catalysts
Ph2 Data
2028-07-21 · 2.3y away
Psoriasis
Ph2 Data
2031-04-18 · 5.0y away
T2D
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04089551 | Phase 2 | Psoriasis | Active | 2836 | OS |
| NCT05807395 | Phase 2 | T2D | Recruiting | 242 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A |